热门资讯> 正文
2023-09-06 20:57
https://www.jnj.com/phase-3-mariposa-2-study-meets-dual-primary-endpoint-resulting-in-statistically-significant-and-clinically-meaningful-improvement-in-progression-free-survival-for-rybrevant-amivantamab-vmjw-plus-chemotherapy-with-and-without-lazertinib-versus-chemotherapy-alone-in-patients-with-egfr-mutated-non-small-cell-lung-cancer-after-disease-progression-on-osimertinib
Mariposa-2是第一个在奥西美替尼治疗后显示在统计学上显著和临床上有意义的无进展生存期(PFS)改善的3期研究
Mariposa-2是第二个RYBREVANT®3期研究,表明有可能改善EGFR突变的非小细胞肺癌患者的预后